{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:42:57Z","timestamp":1786203777146,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000774","name":"The University of Newcastle","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are highly effective cancer therapies. However, they are associated with considerable adverse cardiovascular (CV) outcomes. We investigated the risk factors for CV hospitalisations and all-cause mortality in oncology patients receiving ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study of adult patients administered ICIs between 1st\u00a0January 2010 and 1st\u00a0January 2020 in New South Wales, Australia. Electronic medical records were accessed to obtain demographic and clinical data. Univariate analysis included Chi-squared test for categorical variables and Student\u2019s\n                      <jats:italic>t<\/jats:italic>\n                      -test for continuous variables. Binary logistic regression was used for multivariate analysis. Mortality was analysed using Cox regression including (i) time-dependent Cox models with CV admission as a time-varying covariate and (ii) a 1-year landmark sensitivity analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 1,080 patients receiving ICIs during the study period, 340 patients (31.5%) had at least one CV hospital admission, and 763 patients (70.6%) had died by the end of the follow-up period. On multivariable analysis, prior history of heart failure and\/or cardiomyopathy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), arrhythmia (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and ischaemic heart disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were independently associated with an increased risk of CV hospital admission by approximately fourfold, while CV hospitalisation during follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) was independently associated with an increased risk of all-cause mortality. In a time-dependent Cox model (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009928; excluding CV admissions with missing admission timing), CV admission was associated with higher subsequent mortality (HR 3.29 [95% CI 2.70\u20134.02];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In a 1-year landmark sensitivity analysis among patients alive at 365 days (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009533), CV admission within 1 year was associated with higher subsequent mortality (HR 2.36 [95% CI 1.61\u20133.45];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In cancer patients treated with ICIs, pre-existing CV risk factors significantly increase the risk of CV hospitalisations and all-cause mortality. Appropriate CV risk monitoring and management should be considered for people with cancer receiving ICI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10983-6","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:42:49Z","timestamp":1784241769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-752X","authenticated-orcid":false,"given":"Joshua D.","family":"Bennetts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Van der Westhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina I. C.","family":"Nordman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwol","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-8038","authenticated-orcid":false,"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan T. M.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"10983_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume-title":"Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J (2020) Molecular and cellular functions of CTLA-4. In: Xu J (ed) Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy. Springer Singapore, Singapore, pp 7\u201332"},{"issue":"6","key":"10983_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12470","volume":"279","author":"S Muenst","year":"2016","unstructured":"Muenst S, L\u00e4ubli H, Soysal S, Zippelius A, Tzankov A, Hoeller S (2016) The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 279(6):541\u2013562","journal-title":"J Intern Med"},{"issue":"3","key":"10983_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 12(3):738","journal-title":"Cancers"},{"issue":"6382","key":"10983_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355","journal-title":"Science"},{"key":"10983_CR5","doi-asserted-by":"publisher","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","volume":"13","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhu Y, Xie H, Zou Z (2023) Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol 13:1077468","journal-title":"Front Pharmacol"},{"issue":"1","key":"10983_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.critrevonc.2013.02.007","volume":"88","author":"R Berardi","year":"2013","unstructured":"Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A et al (2013) State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 88(1):75\u201386","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10983_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H L\u00e4ubli","year":"2015","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3(1):11","journal-title":"J Immunother Cancer"},{"key":"10983_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105866","volume":"76","author":"Q Fan","year":"2019","unstructured":"Fan Q, Hu Y, Yang C, Zhao B (2019) Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data. Int Immunopharmacol 76:105866","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10983_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9(2):e013757","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10983_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272022","volume":"17","author":"EB Cone","year":"2022","unstructured":"Cone EB, Haeuser L, Reese SW, Marchese M, Nguyen D-D, Nabi J et al (2022) Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE 17(11):e0272022","journal-title":"PLoS ONE"},{"issue":"24","key":"10983_CR11","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK et al (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142(24):2299\u20132311","journal-title":"Circulation"},{"issue":"16","key":"10983_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","volume":"42","author":"M D\u2019Souza","year":"2021","unstructured":"D\u2019Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C et al (2021) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 42(16):1621\u20131631","journal-title":"Eur Heart J"},{"issue":"29","key":"10983_CR13","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O et al (2022) Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol 40(29):3430\u20133438","journal-title":"J Clin Oncol"},{"issue":"1","key":"10983_CR14","volume":"10","author":"SE Mudra","year":"2024","unstructured":"Mudra SE, Rayes DL, Agrawal A, Kumar AK, Li JZ, Njus M et al (2024) Immune checkpoint inhibitors and pericardial disease: a systematic review. Cardiooncology 10(1):29","journal-title":"Cardiooncology"},{"issue":"10","key":"10983_CR15","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L et al (2024) Cardiovascular toxicities of immune therapies for cancer\u2013a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail 26(10):2055\u20132076","journal-title":"Eur J Heart Fail"},{"key":"10983_CR16","unstructured":"NSW Health. Hunter New England Local Health District. St Leonards, NSW: NSW Government; 2021 [cited 2024 February 13]. Available from: https:\/\/www.health.nsw.gov.au\/lhd\/Pages\/hnelhd.aspx#:~:text=In%202021%20the%20estimated%20population,to%20improve%20rural%20health%20services."},{"key":"10983_CR17","unstructured":"Pharmaceutical Benefits Scheme. Australian Pharmaceutical Benefits Advisory Committee (PBAC) Public Summary Document: Ipilimumab for malignant melanoma Canberra, ACT: Australian Government Department of Health and Aged Care; 2012 [cited 2026 January 7]. Available from: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2012-11\/ipilimumab#:~:text=2.,Public%20Hospital%20Authority%20Required%20(STREAMLINED)."},{"key":"10983_CR18","unstructured":"Pharmaceutical Benefits Scheme. Medicines for the treatment of melanoma Canberra, ACT: Australian Government Department of Health and Aged Care; 2018 [cited 2026 January 7]. Available from: https:\/\/www.pbs.gov.au\/info\/industry\/listing\/participants\/public-release-docs\/2018-05\/medicines-for-the-treatment-of-melanoma."},{"issue":"5","key":"10983_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1159\/000319022","volume":"30","author":"DL Marsden","year":"2010","unstructured":"Marsden DL, Spratt NJ, Walker R, Barker D, Attia J, Pollack M et al (2010) Trends in stroke attack rates and case fatality in the Hunter region, Australia 1996\u20132008. Cerebrovasc Dis 30(5):500\u2013507","journal-title":"Cerebrovasc Dis"},{"key":"10983_CR20","doi-asserted-by":"publisher","first-page":"1144240","DOI":"10.3389\/fcvm.2023.1144240","volume":"10","author":"TD Williams","year":"2023","unstructured":"Williams TD, Kaur A, Warner T, Aslam M, Clark V, Walker R et al (2023) Cardiovascular outcomes of cancer patients in rural Australia. Front Cardiovasc Med 10:1144240","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10983_CR21","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation 133(11):1104\u20131114","journal-title":"Circulation"},{"key":"10983_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.727487","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Y, Han X, Sun J, Li C, Adhikari BK et al (2022) Cardio-oncology: a myriad of relationships between cardiovascular disease and cancer. Frontiers in Cardiovascular Medicine 9:727487","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"48","key":"10983_CR23","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1093\/eurheartj\/ehz645","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Marechal P, Donis N, Oury C (2019) Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. Eur Heart J 40(48):3910\u20133912","journal-title":"Eur Heart J"},{"issue":"2","key":"10983_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","volume":"5","author":"E Bertero","year":"2019","unstructured":"Bertero E, Ameri P, Maack C (2019) Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology. Card Fail Rev 5(2):106\u2013111","journal-title":"Card Fail Rev"},{"issue":"1","key":"10983_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jtho.2023.09.004","volume":"19","author":"S Zhang","year":"2024","unstructured":"Zhang S, Liu L, Shi S, He H, Shen Q, Wang H et al (2024) Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study. J Thorac Oncol 19(1):80\u201393","journal-title":"J Thorac Oncol"},{"key":"10983_CR26","doi-asserted-by":"crossref","unstructured":"Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nature Reviews Cardiology. 2024:1\u201315.","DOI":"10.1038\/s41569-024-01017-x"},{"issue":"5","key":"10983_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaccao.2025.07.001","volume":"7","author":"L Alhuneafat","year":"2025","unstructured":"Alhuneafat L, Guha A, Blaes A, Konety SH (2025) Cancer and cardiovascular disease: shared risk factors, mechanisms, and clinical implications: JACC: CardioOncology state-of-the-art review. JACC CardioOncology 7(5):453\u2013469","journal-title":"JACC CardioOncology"},{"issue":"1","key":"10983_CR28","first-page":"85","volume":"4","author":"DI Paterson","year":"2022","unstructured":"Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A et al (2022) Incident cardiovascular disease among adults with cancer: a population-based cohort study. Cardio Oncology 4(1):85\u201394","journal-title":"Cardio Oncology"},{"issue":"2","key":"10983_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190","journal-title":"Ann Oncol"},{"issue":"1","key":"10983_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40959-024-00269-3","volume":"10","author":"S Liu","year":"2024","unstructured":"Liu S, Horowitz JD, Koczwara B, Sverdlov AL, Packer N, Clark RA (2024) Cardiac events among a cohort of 17,389 patients receiving cancer chemotherapy: short and long term implications. Cardio-Oncology 10(1):72","journal-title":"Cardio-Oncology"},{"issue":"18","key":"10983_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755","journal-title":"N Engl J Med"},{"issue":"11","key":"10983_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y et al (2021) Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor\u2013associated myocarditis: a narrative review. JAMA cardiology 6(11):1329\u20131337","journal-title":"JAMA cardiology"},{"issue":"5","key":"10983_CR33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","volume":"4","author":"GA Suero-Abreu","year":"2022","unstructured":"Suero-Abreu GA, Zanni MV, Neilan TG (2022) Atherosclerosis with immune checkpoint inhibitor therapy. JACC CardioOncology 4(5):598\u2013615","journal-title":"JACC CardioOncology"},{"issue":"6","key":"10983_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002916","volume":"9","author":"K Poels","year":"2021","unstructured":"Poels K, Neppelenbroek SI, Kersten MJ, Antoni ML, Lutgens E, Seijkens TT (2021) Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. J Immunother Cancer 9(6):e002916","journal-title":"J Immunother Cancer"},{"key":"10983_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","volume":"120","author":"J Bar","year":"2019","unstructured":"Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R et al (2019) Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer 120:122\u2013131","journal-title":"Eur J Cancer"},{"key":"10983_CR36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","volume":"196","author":"C Solinas","year":"2020","unstructured":"Solinas C, Saba L, Sganzerla P, Petrelli F (2020) Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review. Thromb Res 196:444\u2013453","journal-title":"Thromb Res"},{"issue":"5","key":"10983_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.hlc.2023.10.008","volume":"33","author":"S Tan","year":"2024","unstructured":"Tan S, Spear E, Sane N, Chan J, Nelson AJ, Alamgeer M et al (2024) Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study. Heart Lung Circ 33(5):721\u2013729","journal-title":"Heart Lung Circ"},{"key":"10983_CR38","unstructured":"Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts Canberra: Australian Institute of Health and Welfare; 2025 [cited 2025 September 30]. Available from: https:\/\/www.aihw.gov.au\/reports\/heart-stroke-vascular-diseases\/hsvd-facts."},{"issue":"1","key":"10983_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bcp.14164","volume":"86","author":"AA Alshehri","year":"2020","unstructured":"Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A (2020) Impact of the pharmacist\u2010led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta\u2010analysis of randomised controlled trials. Br J Clin Pharmacol 86(1):29\u201338","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10983_CR40","first-page":"69","volume":"11","author":"JD Bennetts","year":"2025","unstructured":"Bennetts JD, Williams TD, Beavers CJ, Moore HN, Robson C, Warner T et al (2025) The cardio-oncology multidisciplinary team: beyond the basics. Cardiooncology 11(1):69","journal-title":"Cardiooncology"},{"issue":"5","key":"10983_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082228","volume":"14","author":"J Bennetts","year":"2024","unstructured":"Bennetts J, White J, Croft H, Cooper J, McIvor D, Eadie N et al (2024) Pharmacist-led medication management services: a qualitative exploration of transition-of-care cardiovascular disease patient experiences. BMJ Open 14(5):e082228","journal-title":"BMJ Open"},{"key":"10983_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100970","author":"A Rousseau","year":"2024","unstructured":"Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D et al (2024) Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100970","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10983_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi F, Middleton MR (2022) Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am J Clin Dermatol 23(3):331\u2013338","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10983_CR44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 5(10):1411\u20131420","journal-title":"JAMA Oncol"},{"issue":"10","key":"10983_CR45","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34(10):1122\u20131130","journal-title":"J Clin Oncol"},{"key":"10983_CR46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","volume":"164","author":"S Gernaat","year":"2017","unstructured":"Gernaat S, Ho P, Rijnberg N, Emaus M, Baak L, Hartman M et al (2017) Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 164:537\u2013555","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10983_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15639-5","volume":"11","author":"KC Stoltzfus","year":"2020","unstructured":"Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM et al (2020) Fatal heart disease among cancer patients. Nat Commun 11(1):2011","journal-title":"Nat Commun"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10983-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:55:43Z","timestamp":1786200943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10983-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10983"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10983-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Exemption from human research ethics review was granted by the Hunter New England Research Ethics Manager (authorisation number AU202210-08).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"770"}}